ArticleJAC-antimicrobial resistance2025

First-in-human study of the benzothiazinone and DprE1 inhibitor BTZ-043, a novel drug candidate for the treatment of Tuberculosis.

Wandini Lutchmun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.